26839 Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks

Abstract

Background: Atopic dermatitis (AD) affects different anatomic regions; some adults may exhibit more localized AD, such as head and neck involvement. We analyzed the extent of improvement in AD signs across different anatomic regions at Week 52 using data from the phase 3 dupilumab trial, LIBERTY AD CHRONOS (NCT02260986).